Should You Worry About This News in Moderna's Investigational Coronavirus Vaccine Report?
This week, Moderna (NASDAQ: MRNA) took another step toward the finish line in the coronavirus vaccine race. On Monday, the biotech company applied for Emergency Use Authorization (EUA) for its investigational vaccine. The move follows the submission by rival team Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) ten days earlier.
Moderna said its vaccine candidate was well tolerated. And efficacy, at 94.1%, was well above the 50% bar set by the U.S. Food and Drug Administration (FDA). But that metric might have disappointed some.
Efficacy after the company's first interim review of the trial was at 94.5%. So efficacy declined, albeit slightly, as coronavirus cases accrued. Pfizer's efficacy increased from the first review to the second -- from 90% to 95%. Should we be worried about Moderna? And does this give Pfizer an edge?
Source Fool.com
